Doseology Uplists to OTCQB as DOSEF, Expanding U.S. Investor Access to the Emerging Oral Stimulant Pouch Category
MWN-AI** Summary
Doseology Sciences Inc., trading on the Canadian Securities Exchange under the ticker MOOD, has announced the successful uplisting of its common shares to the OTCQB Venture Market, where it will trade as DOSEF. This strategic move significantly broadens U.S. investor access to Doseology's innovative oral stimulant pouch products, which cater to the growing consumer preference for smoke-free and discreet delivery methods.
Doseology specializes in the emerging oral stimulant pouch market, identified as one of the fastest-growing sectors within the stimulant and nicotine markets. With a focus on developing proprietary stimulant technologies and intellectual property, the company aims to create controlled-dose stimulant products in portable formats. The oral pouch category aligns with evolving consumer demands, moving away from traditional energy delivery methods such as beverages and nicotine products toward alternatives that prioritize convenience and discretion.
CEO Chris Jackson expressed confidence that trading on the OTCQB will enhance transparency and governance for investors, fostering confidence as the company executes its long-term growth strategy in a competitive market. The OTCQB's requirements for financial reporting and compliance are expected to support Doseology's ambitions as it grows its brand portfolio and product offerings.
Additionally, the company appointed Larry Latowsky as Executive Chairman, whose expertise will strengthen the governance framework necessary for continued compliance with new market standards.
Overall, Doseology is well-positioned to capture market share in the dynamic oral stimulant sector, particularly as it continues to innovate within this niche and expand its consumer-facing product lines, including through its recent acquisition of the brand Feed That Brain. The company's strategic focus on direct-to-consumer distribution and product development aims to establish a scalable ecosystem in this high-growth category.
MWN-AI** Analysis
Doseology Sciences Inc. (CSE: MOOD, OTCQB: DOSEF) is positioning itself strategically within the burgeoning oral stimulant pouch market, having recently uplisted to the OTCQB. This move provides U.S. investors increased access to a sector projected for significant growth as demand for smoke-free delivery methods rises.
The oral pouch market is experiencing heightened interest due to changing consumer preferences towards discreet, easy-to-use options, particularly in an era where health considerations overshadow traditional smoking and vaping products. Notably, major industry players like Philip Morris and British American Tobacco are investing heavily in innovative oral delivery formats, underscoring the category's potential.
Doseology's strategic decisions, including the appointment of a seasoned executive to ensure compliance and transparency, reflect a proactive approach to governance as it enters this new trading environment. This governance elevation is essential given the heightened investor scrutiny that comes with U.S. market exposure; thus, ensuring meticulous financial reporting will be critical.
Investors should also scrutinize Doseology’s product diversity, notably the innovative stimulant technologies and the integration of the "Feed That Brain" retail brand into its portfolio. This underscores the company's commitment to enhancing its distribution capabilities, aligning with market demand for novel stimulant products.
Given the landscape of the oral pouch market and the Company’s solid strategic positioning, there exists a favorable market outlook for DOSEF. Investors would benefit from monitoring Doseology's developments closely, particularly in product innovation and market penetration strategies. While the risks of volatility and market adaptation remain, Doseology's approach can propose a promising avenue for growth in a competitive sector. It's essential to remain informed regarding market trends and financial performance to make well-founded investment decisions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Canada NewsWire
KELOWNA, BC, March 11, 2026 /CNW/ -- Doseology Sciences Inc. (CSE: MOOD) (OTCQB: DOSEF) (FSE: VU70) ("Doseology" or the "Company") a consumer product innovation company focused on oral stimulant pouch technologies, is pleased to announce that its common shares have commenced trading on the OTCQB® Venture Market in the United States under the symbol DOSEF.
"We are pleased to expand trading access for U.S. investors through the OTCQB market," said Chris Jackson, Chief Executive Officer of Doseology Sciences Inc. "The United States represents both the largest capital market and one of the most important consumer markets for modern oral stimulant products, and this milestone supports our long?term growth strategy. Trading on OTCQB aligns the Company with higher standards of financial reporting and disclosure, providing greater transparency and confidence for investors as we execute our long-term growth strategy."
The OTCQB is designed for developing and growth-stage public companies that meet higher transparency and governance standards. The OTCQB Venture Market provides investors with greater comfort because companies must maintain current financial reporting, management certification, and ongoing compliance standards.
Further to the company's commitment to adhering to transparency and required reporting for our new listing we have recently announced the appointment of Larry Latowsky as Executive Chairman of the Board of Directors. Mr. Latowsky's years of experience on public and private boards with specialized experiences and knowledge will support our compliance with new markets.
Industry Context
The oral pouch category has emerged as one of the fastest?growing segments within the broader stimulant and nicotine markets, as consumers increasingly shift toward smoke?free and discreet delivery formats. Global companies including Philip Morris International and British American Tobacco have made significant investments in modern oral products as demand for alternative delivery formats continues to expand.
The global energy drink market represents a multi?billion?dollar consumer category, with increasing innovation focused on new delivery formats beyond traditional beverages. Oral pouch technologies are emerging as a potential complementary format for delivering controlled?dose stimulant products in a convenient and portable form.
Strategic Positioning
Doseology is positioning itself as one of the early pure?play public companies focused on the emerging oral stimulant pouch category, combining consumer product development and direct?to?consumer distribution strategies.
The Company is also exploring the development of proprietary stimulant technologies and intellectual property, including next?generation caffeine analog and nicotine?alternative compounds designed for modern oral delivery formats.
As consumer demand evolves toward portable, controlled?dose stimulant delivery formats, Doseology believes oral stimulant pouches may represent a new product segment within the broader global energy and functional stimulant market.
Platform Strategy
Doseology is pursuing a platform approach to oral stimulant innovation, combining product development, brand creation, and digital distribution to launch multiple consumer?facing stimulant products designed for modern lifestyles.
Through its growing brand portfolio and direct?to?consumer platforms, including Doseology's recently acquired retail brand Feed That Brain, the Company aims to build a scalable ecosystem of functional stimulant products within the emerging oral delivery category.
The Company announces that, further to its news release of August 27, 2025 that announced the closing of the acquisition of the "Feed That Brain" division operated by Joseph Mimran & Associates Inc. (the "Vendor"), it has issued an aggregate of 75,000 pre-funded warrants (the "Pre-Funded Warrants") to the Vendor, based upon a deemed price of $1.00 per Pre-funded Warrant. Additional issuances of $75,000 of Pre-Funded Warrants are due on the one (1) year and eighteen (18) month anniversaries of the closing the acquisition in accordance with the asset purchase and sale agreement executed between the parties. The Pre-Funded Warrants are subject to a four-month hold period in accordance with applicable securities laws, which will expire on July 11, 2026.
About Doseology Sciences Inc. (CSE: MOOD | OTCQB: DOSEF | FSE: VU70)
Doseology Sciences Inc. specializes in pouch-based oral stimulant and cognitive support products. The rapidly expanding oral stimulant pouch sector is gaining momentum as consumers seek modern, discreet alternatives to traditional delivery formats. Unlike combustible tobacco or vape products, oral stimulant pouches are smokeless and vapor-free, providing an alternative delivery method without inhalation.
From a market perspective, the oral pouch category is experiencing strong global growth as consumers increasingly prioritize convenience, portability, and format innovation. The pouch sector represents one of the most dynamic and high-growth areas in modern functional consumer products.
For more information visit:
Corporate: www.doseology.com
Shop: www.feedthatbrain.com
On behalf of the Board of Directors,
Chris Jackson
CEO, Director
Doseology Sciences Inc.
Investor & Media Contact:
Email: hello@doseology.com
Phone: 604.908.3095
Forward Looking Statements
This press release contains statements that constitute "forward?looking information" within the meaning of applicable securities laws. Forward?looking information is often identified by the words "may," "would," "could," "should," "will," "intend," "plan," "anticipate," "believe," "estimate," "expect" or similar expressions. Readers are cautioned that forward?looking information is not based on historical facts but instead reflects the Company's management's expectations, estimates or projections concerning the business of the Company's future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward?looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance, or achievements. Among the key factors that could cause actual results to differ materially from those projected in the forward?looking information are the following: changes in general economic, business and political conditions, including changes in the financial markets; decreases in the prevailing prices for products in the markets that the Company operates in; adverse changes in applicable laws or adverse changes in the application or enforcement of current laws; regulations and enforcement priorities of governmental authorities; compliance with government regulation and related costs; and other risks described in the Company's prospectus. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward?looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated, or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward?looking information except as otherwise required by applicable law. For more information, investors should review the Company's filings which are available on SEDAR+.
No securities regulatory authority has either approved or disapproved of the contents of this press release.
Logo: https://mma.prnewswire.com/media/2858641/5858235/Doseology_Sciences_Inc_Logo.jpg
SOURCE Doseology Sciences Inc.
View original content: http://www.newswire.ca/en/releases/archive/March2026/11/c5949.html
FAQ**
How does Doseology Sciences DOSEF plan to leverage its recent uplisting to the OTCQB to enhance investor confidence and broaden its market presence in the rapidly growing oral stimulant pouch category?
What specific strategies is Doseology Sciences DOSEF implementing to compete against established players like Philip Morris International and British American Tobacco in the oral pouch market?
In what ways does Doseology Sciences DOSEF intend to utilize its recent acquisition of the "Feed That Brain" brand to enhance its product portfolio and consumer outreach?
Can you elaborate on the proprietary stimulant technologies and intellectual property that Doseology Sciences DOSEF is exploring to position itself as a leader in the oral stimulant pouch segment?
**MWN-AI FAQ is based on asking OpenAI questions about Doseology Sciences (OTC: DOSEF).
NASDAQ: DOSEF
DOSEF Trading
0.0% G/L:
$0.5475 Last:
500 Volume:
$0.5475 Open:
